Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



2 New Treatments for Relapsing-Remitting MS Now Available in New Zealand

The Multiple Sclerosis Society of New Zealand (MSNZ) announced that PHARMAC has agreed with its request to finance two novel first-in-line therapies for relapsing-remitting forms of multiple sclerosis (MS), making them accessible to patients there.

PHARMAC recently agreed to fund the two treatments, teriflunomide (Aubagio), supplied by Sanofi-Aventis NZ, and dimethyl fumarate (Tecfidera), provided by Biogen NZ. Both medicines will be available in the community and District Health Board (DHB) Hospitals, with the same restrictions as the MS drugs fingolimod (Gilenya) and natalizumab (Tysabri), which PHARMAC granted access to in 2014. PHARMAC is the government agency responsible for deciding which pharmaceuticals will be publicly fund in New Zealand.

“There are approximately 4,000 people with multiple sclerosis in New Zealand,” said MSNZ spokesman, Neil Woodhams, in a news release. “This announcement is a really positive step forward for them.”

Added Woodhams: “This time last year PHARMAC extended the access criteria for Tysabri and Gilenya, and we are seeing how that change is making a difference in people’s lives. We know from figures that PHARMAC has provided that 471 people with MS have been approved to receive Tysabri or Gilenya within the first 12 months of funding. We hope that the impact of access to Tecfidera and Aubagio will be just as positive.”

MSNZ says it is concerned, however, about the criteria established for treatment, a point it addressed in its submission to PHARMAC in October. “We are still concerned the overall entry and exit criteria are too tight,” said Woodhams. “There needs to be some flexibility. New Zealand is the only country to have such stringent exit criteria under the Expanded Disability Status Scale (EDSS).”

Specifically, “Some people diagnosed with relapsing/remitting MS unfortunately experience a high number of relapses that produce disability in the long or medium term. In some instances a person may have attacks of the spinal cord that leave them with permanent disability in their movement. As per the EDSS scale, this will put them over point that they can enter into treatment. However their poor recovery does not mean that they have a more progressive form of MS but are still considered relapsing/remitting,” he said, adding, “[w]e remain concerned for patients who have had their first demyelinating episode (CIS) with proven MRI activity and demonstrable symptoms of MS, and who would benefit from early treatment, still have to wait for a significant relapse.”

MSNZ is asking for reassurance from PHARMAC that its concerns will be considered fairly. “PHARMAC have advised that applications can be made if circumstances are outside the criteria; however, we would like more reassurance these will be fully considered,” Woodhams concluded.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Go to Newer News Go to Older News